Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Femasys Inc. - Common Stock (NQ:FEMY)

1.250 -0.040 (-3.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 196,382
Open 1.260
Bid (Size) 1.250 (1)
Ask (Size) 1.340 (125)
Prev. Close 1.290
Today's Range 1.180 - 1.290
52wk Range 0.8600 - 1.840
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Femasys Reports Wider-Than-Expected Annual Loss, But Retail Continues To Be Optimistic
The company said that as of the end of 2024, it had an accumulated deficit of $127.2 million and cash and cash equivalents of only $3.5 million. 
Via Stocktwits
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire

Performance

YTD
+13.6%
+13.6%
1 Month
-18.8%
-18.8%
3 Month
+13.6%
+13.6%
6 Month
+12.6%
+12.6%
1 Year
-27.3%
-27.3%

More News

Read More
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations
From Femasys Inc.
Via GlobeNewswire
The Latest Analyst Ratings For Femasys
Via Benzinga
Femasys Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
Via ACCESS Newswire
Assessing Femasys: Insights From 4 Financial Analysts
Via Benzinga
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain
From Femasys Inc.
Via GlobeNewswire
Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials
From Femasys Inc.
Via GlobeNewswire
Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Femasys to Exhibit at the Annual AAGL 2024 Global Conference
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed
From Femasys Inc.
Via GlobeNewswire
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program
From Femasys Inc.
Via GlobeNewswire
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
From Femasys Inc.
Via GlobeNewswire
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Infertility Clinic Customers from Coast to Coast
From Femasys Inc.
Via GlobeNewswire
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market
From Femasys Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Femasys Inc. - Common Stock publicly traded?
Yes, Femasys Inc. - Common Stock is publicly traded.
What exchange does Femasys Inc. - Common Stock trade on?
Femasys Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Femasys Inc. - Common Stock?
The ticker symbol for Femasys Inc. - Common Stock is FEMY on the Nasdaq Stock Market
What is the current price of Femasys Inc. - Common Stock?
The current price of Femasys Inc. - Common Stock is 1.250
When was Femasys Inc. - Common Stock last traded?
The last trade of Femasys Inc. - Common Stock was at 03/31/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.